

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jeppesen et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: February 8, 2002

Examiner: To be assigned

For: Substituted Hetero-Polycyclic Compounds as PPAR $\alpha$  and PPAR $\gamma$  Activators (As Amended)

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

**IN THE TITLE OF THE INVENTION:**

Please delete "New Compounds, Their Preparation and Use" and replace it with  
-- Substituted Hetero-Polycyclic Compounds as PPAR $\alpha$  and PPAR $\gamma$  Activators --

**IN THE SPECIFICATION:**

At page 1, after the title, insert

**--CROSS-REFERENCE TO RELATED APPLICATIONS**


This application is a divisional application of application serial no. 09/419,761 filed October 19, 1999, now allowed, which claims priority under 35 U.S.C. 119 of Danish application PA 1998 01352 filed October 21, 1998, and of U.S. Provisional application 60/105,912 filed October 28, 1998, the contents of which are fully incorporated herein by reference.--

IN THE CLAIMS:

Please cancel claims 3-6, 8-16, 18-44, 48-52, and 56-60 without prejudice or disclaimer.

Please substitute the following amended claims for the pending claims having the same claim numbers (a marked-up version pursuant to 37 C.F.R. 1.21 is attached hereto):

1. (Amended) A compound of formula (Ia)



wherein  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or  $C_{1-12}$ -alkyl,  $C_{4-12}$ -alkenynyl,  $C_{2-12}$ -alkenyl,  $C_{2-12}$ -alkynyl,  $C_{1-12}$ -alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxy $C_{1-12}$ -alkyl, amino, acylamino,  $C_{1-12}$ -alkylamino, arylamino, aralkylamino, amino $C_{1-12}$ -alkyl,  $C_{1-12}$ -alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,  $C_{1-12}$ -alkoxy $C_{1-12}$ -alkyl, aryloxy $C_{1-12}$ -alkyl, aralkoxy $C_{1-12}$ -alkyl,  $C_{1-12}$ -alkylthio, thio $C_{1-12}$ -alkyl,  $C_{1-12}$ -alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,  $-COR^{11}$ , or  $-SO_2R^{12}$ , wherein  $R^{11}$  and  $R^{12}$  independently of each other are selected from hydroxy, halogen, perhalomethyl,  $C_{1-6}$ -alkoxy or amino optionally substituted with one or more  $C_{1-6}$ -alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

or R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup> and/or R<sup>3</sup> and R<sup>4</sup> may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more C<sub>1-6</sub>-alkyl;

ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy or C<sub>1-7</sub>-alkyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, C<sub>1-7</sub>-alkoxy or aryl;

X is -S-(CHR<sup>9</sup>)-, -(NR<sup>9</sup>)-S(O<sub>2</sub>)-, -CH<sub>2</sub>-(SO)-, -(SO)-, -(SO<sub>2</sub>)-, -CH<sub>2</sub>-(SO<sub>2</sub>)-, wherein R<sup>9</sup> is hydrogen, halogen, hydroxy, nitro, cyano, formyl, C<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, C<sub>1-12</sub>-alkylamino, arylamino, aralkylamino, aminoC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C<sub>1-12</sub>-alkoxyC<sub>1-12</sub>-alkyl, aryloxyC<sub>1-12</sub>-alkyl, aralkoxyC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkylthio, thioC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>13</sup>, or -SO<sub>2</sub>R<sup>14</sup>, wherein R<sup>13</sup> and R<sup>14</sup> independently of each other are selected from hydroxy, halogen, C<sub>1-6</sub>-alkoxy, amino optionally substituted with one or more C<sub>1-6</sub>-alkyl, perhalomethyl or aryl;

Ar represents arylene or heteroarylene, optionally substituted with one or more C<sub>1-6</sub>-alkyl or aryl;

R<sup>5</sup> represents hydrogen, hydroxy, halogen, C<sub>1-12</sub>-alkoxy, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R<sup>5</sup> forms a bond together with R<sup>6</sup>,

R<sup>6</sup> represents hydrogen, hydroxy, halogen, C<sub>1-12</sub>-alkoxy, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, acyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R<sup>6</sup> forms a bond together with R<sup>5</sup>,

R<sup>7</sup> represents hydrogen, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, aryl, aralkyl, C<sub>1-12</sub>-alkoxyC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonyl, aryloxycarbonyl, C<sub>1-12</sub>-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

R<sup>8</sup> represents hydrogen, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

Y represents oxygen, sulphur or NR<sup>10</sup>, where R<sup>10</sup> represents hydrogen, C<sub>1-12</sub>-alkyl, aryl, hydroxyC<sub>1-12</sub>-alkyl or aralkyl groups or when Y is NR<sup>10</sup>, R<sup>8</sup> and R<sup>10</sup> may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C<sub>1-6</sub>-alkyl;

n is an integer ranging from 1 to 4 and m is an integer ranging from 0 to 1;

or a pharmaceutically acceptable salt thereof.

2. (Not amended) A compound according to claim 1 wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C<sub>1-7</sub>-alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, C<sub>1-7</sub>-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC<sub>1-7</sub>-alkyl, amino, acylamino, C<sub>1-7</sub>-alkylamino, arylamino, aralkylamino, aminoC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkoxyC<sub>1-7</sub>-alkyl, aryloxyC<sub>1-7</sub>-alkyl, aralkoxyC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkylthio, thioC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C<sub>1-6</sub>-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano; or R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup> and/or R<sup>3</sup> and R<sup>4</sup> may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more C<sub>1-6</sub>-alkyl.

7. (Amended) A compound according to claim 1 wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C<sub>1-7</sub>-alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, C<sub>1-7</sub>-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC<sub>1-7</sub>-alkyl, amino, acylamino, C<sub>1-7</sub>-alkylamino, arylamino, aralkylamino, aminoC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkoxyC<sub>1-7</sub>-alkyl, aryloxyC<sub>1-7</sub>-alkyl, aralkoxyC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkylthio, thioC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, perhalomethyl or

amino optionally substituted with one or more C<sub>1-6</sub>-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

17. (Amended) A compound according to claim 1 wherein Ar represents arylene or heteroarylene;

R<sup>5</sup> represents hydrogen, hydroxy, halogen; or R<sup>5</sup> forms a bond together with R<sup>6</sup>,

R<sup>6</sup> represents hydrogen, hydroxy, halogen; or R<sup>6</sup> forms a bond together with R<sup>5</sup>,

R<sup>7</sup> represents hydrogen, C<sub>1-7</sub>-alkyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, aryl, aralkyl, C<sub>1-7</sub>-alkoxyC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

R<sup>8</sup> represents hydrogen, C<sub>1-7</sub>-alkyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl;

Y represents oxygen or sulphur;

n is an integer ranging from 2 to 3 and m is 1.

45. (Amended) The compound according to claim 1 which is

2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzoyloxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diazadibenzo[a,d]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diazadibenzo[a,d]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diazadibenzo[a,d]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[1-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-methoxy]-phenyl}-propionic acid,  
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,  
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
 3-(4-(1-(2-Chloro-5-oxo-phenothiazin-10-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,  
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,  
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,  
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-methoxy-propionic acid,  
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,  
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,  
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-propoxy-propionic acid,  
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-methoxy-propionic acid,

3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid, or a pharmaceutically acceptable salt thereof.

46. The compound according to claim 1 which is

2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,  
2-Ethoxy-3-{4-[2-(5-oxo-5*H*-5<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid; or a pharmaceutically acceptable salt thereof.

47. (Amended) A pharmaceutical composition comprising, as an active ingredient, a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

53. (Amended) A method for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

54. (Amended) A method for the treatment of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

55. (Amended) A method for the treatment of diabetes or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

## REMARKS


Entry of this preliminary amendment is respectfully requested.

This application is a divisional of copending application no. 09/419,761, now allowed.

Claims 3-6, 8-16, 18-44, 48-52 and 56-60 have been cancelled without prejudice or disclaimer. Claims 1, 7, 17, 45-47, and 53-55 are amended to remove nonelected subject matter and to correct multiple dependencies. Claims 1, 2, 7, 17, 45-47, and 53-55 are based on the corresponding claims as originally filed in the parent application and are directed to the subject matter of **Group IV** which was not elected in the parent application. In addition, the title of the invention has been amended to more accurately define the claimed invention. Accordingly, claims 1, 2, 7, 17, 45-47, and 53-55 are pending and at issue in this application.

It is respectfully submitted that the present amendment presents no new issues or new matter and that the claims are in condition for allowance, and a determination to that effect is earnestly solicited. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Date: February 8, 2002

Peter J. Waibel, Reg. No. 43,228  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123




23650

PATENT TRADEMARK OFFICE



MARKED-UP VERSION OF THE CLAIMS SHOWING AMENDMENTS MADE

1. (Amended) A compound of formula (Ia)



wherein  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or  $C_{1-12}$ -alkyl,  $C_{4-12}$ -alkenynyl,  $C_{2-12}$ -alkenyl,  $C_{2-12}$ -alkynyl,  $C_{1-12}$ -alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxy $C_{1-12}$ -alkyl, amino, acylamino,  $C_{1-12}$ -alkylamino, arylamino, aralkylamino, amino $C_{1-12}$ -alkyl,  $C_{1-12}$ -alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,  $C_{1-12}$ -alkoxy $C_{1-12}$ -alkyl, aryloxy $C_{1-12}$ -alkyl, aralkoxy $C_{1-12}$ -alkyl,  $C_{1-12}$ -alkylthio, thio $C_{1-12}$ -alkyl,  $C_{1-12}$ -alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,  $-COR^{11}$ , or  $-SO_2R^{12}$ , wherein  $R^{11}$  and  $R^{12}$  independently of each other are selected from hydroxy, halogen, perhalomethyl,  $C_{1-6}$ -alkoxy or amino optionally substituted with one or more  $C_{1-6}$ -alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

or  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$  and/or  $R^3$  and  $R^4$  may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more  $C_{1-6}$ -alkyl;

ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more [halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or  $C_{1-12}$ -alkyl,  $C_{4-12}$ -alkenynyl,  $C_{2-12}$ -alkenyl,  $C_{2-12}$ -alkynyl,  $C_{1-12}$ -alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl,

heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC<sub>1-12</sub>-alkyl, amino, acylamino, C<sub>1-12</sub>-alkylamino, arylamino, aralkylamino, aminoC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C<sub>1-12</sub>-alkoxyC<sub>1-12</sub>-alkyl, aryloxyC<sub>1-12</sub>-alkyl, aralkoxyC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkylthio, thioC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, halogen, perhalomethyl, C<sub>1-6</sub>-alkoxy or amino optionally substituted with one or more C<sub>1-6</sub>-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano] hydrogen, halogen, perhalomethyl, hydroxy or C<sub>1-7</sub>-alkyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, C<sub>1-7</sub>-alkoxy or aryl;

X is [a valence bond, -(CHR<sup>9</sup>)-, -(CHR<sup>9</sup>)-CH<sub>2</sub>-, -CH=CH-, -O-(CHR<sup>9</sup>)-,] -S-(CHR<sup>9</sup>)-, [- (NR<sup>9</sup>)-CH<sub>2</sub>-, -(CHR<sup>9</sup>)-CH=CH-, -(CHR<sup>9</sup>)-CH<sub>2</sub>-CH<sub>2</sub>-, -(C=O)-, -O-CH<sub>2</sub>-O-,] - (NR<sup>9</sup>)-S(O<sub>2</sub>)-, [-CH=(CR<sup>9</sup>)-, -(CO)-(CHR<sup>9</sup>)-,] -CH<sub>2</sub>-(SO)-, -(SO)-, -(SO<sub>2</sub>)-, -CH<sub>2</sub>-(SO<sub>2</sub>)-, [-CH<sub>2</sub>-O-CH<sub>2</sub>-,] wherein R<sup>9</sup> is hydrogen, halogen, hydroxy, nitro, cyano, formyl, C<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, C<sub>1-12</sub>-alkylamino, arylamino, aralkylamino, aminoC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C<sub>1-12</sub>-alkoxyC<sub>1-12</sub>-alkyl, aryloxyC<sub>1-12</sub>-alkyl, aralkoxyC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkylthio, thioC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>13</sup>, or -SO<sub>2</sub>R<sup>14</sup>, wherein R<sup>13</sup> and R<sup>14</sup> independently of each other are selected from hydroxy, halogen, C<sub>1-6</sub>-alkoxy, amino optionally substituted with one or more C<sub>1-6</sub>-alkyl, perhalomethyl or aryl;

Ar represents arylene[,] or heteroarylene, [or a divalent heterocyclic group] optionally substituted with one or more C<sub>1-6</sub>-alkyl or aryl;

R<sup>5</sup> represents hydrogen, hydroxy, halogen, C<sub>1-12</sub>-alkoxy, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R<sup>5</sup> forms a bond together with R<sup>6</sup>,

R<sup>6</sup> represents hydrogen, hydroxy, halogen, C<sub>1-12</sub>-alkoxy, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, acyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R<sup>6</sup> forms a bond together with R<sup>5</sup>,  
R<sup>7</sup> represents hydrogen, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, aryl, aralkyl, C<sub>1-12</sub>-alkoxyC<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxycarbonyl, aryloxycarbonyl, C<sub>1-12</sub>-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;  
R<sup>8</sup> represents hydrogen, C<sub>1-12</sub>-alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;  
Y represents oxygen, sulphur or NR<sup>10</sup>, where R<sup>10</sup> represents hydrogen, C<sub>1-12</sub>-alkyl, aryl, hydroxyC<sub>1-12</sub>-alkyl or aralkyl groups or when Y is NR<sup>10</sup>, R<sup>8</sup> and R<sup>10</sup> may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C<sub>1-6</sub>-alkyl;  
n is an integer ranging from 1 to 4 and m is an integer ranging from 0 to 1;  
or a pharmaceutically acceptable salt thereof.

7. (Amended) A compound according to [anyone of the preceding claims] claim 1 wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C<sub>1-7</sub>-alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, C<sub>1-7</sub>-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC<sub>1-7</sub>-alkyl, amino, acylamino, C<sub>1-7</sub>-alkylamino, arylamino, aralkylamino, aminoC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkoxyC<sub>1-7</sub>-alkyl, aryloxyC<sub>1-7</sub>-alkyl, aralkoxyC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkylthio, thioC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C<sub>1-6</sub>-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

17. (Amended) A compound according to [anyone of the preceding claims] claim 1 wherein Ar represents arylene or heteroarylene;  
R<sup>5</sup> represents hydrogen, hydroxy, halogen; or R<sup>5</sup> forms a bond together with R<sup>6</sup>,  
R<sup>6</sup> represents hydrogen, hydroxy, halogen; or R<sup>6</sup> forms a bond together with R<sup>5</sup>,

R<sup>7</sup> represents hydrogen, C<sub>1-7</sub>-alkyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, aryl, aralkyl, C<sub>1-7</sub>-alkoxyC<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

R<sup>8</sup> represents hydrogen, C<sub>1-7</sub>-alkyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl;

Y represents oxygen or sulphur;

n is an integer ranging from 2 to 3 and m is 1.

45. (Amended) The compound according to claim 1 which is

[3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,  
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,  
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,  
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-benzyloxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,  
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,  
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-methoxy-propionic acid,  
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-2-ethoxy-propionic acid,  
2-Ethoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Methoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Propoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Benzyloxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Ethoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,

2-Methoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,

2-Benzoyloxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,

2-Ethoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,

2-Methoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,

2-Benzoyloxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,

2-Ethoxy-3-(4-[1-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-methoxy]-phenyl)-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-benzoyloxy-propionic acid,

3-{4-[1-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-methoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propoxy]-phenyl}-2-benzoyloxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propyl]-phenyl}-2-methoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propyl]-phenyl}-2-benzyloxy-propionic acid,

2-Ethoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[1-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-methoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diazadibenzo[a,d]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,  
 [2-Ethoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[1-(9-oxo-9*H*-acridin-10-yl)-methoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[2-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Propoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Methoxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,  
 2-Ethoxy-3-{4-[1-(5-oxo-5*H*-5*H*<sup>4</sup>-phenothiazin-10-yl)-methoxy]-phenyl}-propionic acid,  
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,



3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
3-(4-(1-(2-Chloro-5-oxo-phenothiazin-10-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-methoxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-propoxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-methoxy-propionic acid,  
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,  
[(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,  
(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
(S)-3-(4-(1-(Betacarbolin-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-methoxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-methoxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-propoxy-propionic acid,  
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,  
3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,  
3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
3-(4-(1-(Dibenzo[*b,f*]azepin-5-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,  
3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,  
3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,

3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,  
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,  
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-propoxy-propionic acid,  
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-ethoxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-methoxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-propoxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-benzyloxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-ethoxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-methoxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-propoxy-propionic acid,  
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-benzyloxy-propionic acid,  
 2-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-ethoxy-propionic acid,  
 2-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-propoxy-propionic acid,  
 1-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-methoxy)-phenyl-2-ethoxy-propionic acid,  
 2-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-benzyloxy-propionic acid,  
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,  
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
 (S) 3-(4-(1-(3-Phenyl-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(3-(3-Phenyl-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(3-(3-Phenyl-carbazol-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3-Benzyl-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3-(2-Pyridyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3-(3-Furanyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3-(2-thionyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
 (S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
 (S) 3-(4-(1-(3-Bromo-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(3-(3-Bromo-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid

(S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
 (S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,  
 (S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,  
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,  
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
 (S) 3-(4-(1-(3,6 Dibromo-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(3-(3,6 Dibromo-carbazol-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(3-(3,6 Dibromo-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-methoxy-propionic acid,  
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-propoxy-propionic acid,  
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-benzyloxy-propionic acid,  
 (S) 3-(4-(1-Carbazol-9-yl-methoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(3-Carbazol-9-yl-propoxy)-phenyl)-2-ethoxy-propionic acid,  
 (S) 3-(4-(3-Carbazol-9-yl-propyl)-phenyl)-2-ethoxy-propionic acid;]  
 or a pharmaceutically acceptable salt thereof.

46. The compound according to claim 1 which is

[3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,  
 2-Ethoxy-3-{4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl}-  
 propionic acid,  
 3-{4-[2-(6,7-Dihydro-5H-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-ethoxy-propionic  
 acid,  
 2-Ethoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic  
 acid,  
 2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,]  
 2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10<sup>6</sup>-thia-5,11-diaza-  
 dibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

[2-Ethoxy-3-{4-[2-(9-oxo-9H-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,]  
2-Ethoxy-3-{4-[2-(5-oxo-5H-5<sup>4</sup>-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid; or a  
pharmaceutically acceptable salt thereof.

47. (Amended) A pharmaceutical composition comprising, as an active ingredient, a  
compound according to [anyone of the preceding compound claims] claim 1 or a  
pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier  
or diluent.

53. (Amended) A method for the treatment of ailments, the method comprising administering  
to a subject in need thereof an effective amount of a compound according to [anyone of the  
preceding compound claims] claim 1 or a pharmaceutically acceptable salt thereof[, or of a  
composition according to anyone of the preceding composition claims].

54. (Amended) A method for the treatment [and/or prevention] of conditions mediated by  
nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the  
method comprising administering to a subject in need thereof an effective amount of a  
compound according to [anyone of the preceding compound claims] claim 1 or a  
pharmaceutically acceptable salt thereof[, or of a composition according to anyone of the  
preceding claims 47-52].

55. (Amended) A method for the treatment [and/or prevention] of diabetes [and/]or obesity,  
the method comprising administering to a subject in need thereof an effective amount of a  
compound according to [anyone of the preceding compound claims] claim 1 or a  
pharmaceutically acceptable salt thereof[, or of a composition according to anyone of the  
preceding claims 47-52].

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jeppesen et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: February 8, 2002

Examiner: To be assigned

For: Substituted Hetero-Polycyclic Compounds as PPAR $\alpha$  and PPAR $\gamma$   
Activators (As Amended)

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN 09/419,761 filed on October 19, 1999, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. Abstract of Japanese Patent No. JP 10182550;
2. WO 97/36579;
3. WO 97/25042;


4. WO 96/04261;
5. WO 96/04260; and
6. WO 99/193131.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Date: February 8, 2002

Respectfully submitted,



Peter J. Waibel, Reg. No. 43,228  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE